These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Biological determinants of bladder cancer gene expression subtypes. Aine M; Eriksson P; Liedberg F; Sjödahl G; Höglund M Sci Rep; 2015 Jun; 5():10957. PubMed ID: 26051783 [TBL] [Abstract][Full Text] [Related]
31. [Update on molecular classifications and new histological classification of bladder cancer]. Varinot J; Furudoï A; Roupret M; Compérat E Prog Urol; 2016; 26(11-12):600-607. PubMed ID: 27663304 [TBL] [Abstract][Full Text] [Related]
32. Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy. Hesswani C; Jackson CL; Marcq G; Hardy C; Kool R; Mansure JJ; Brimo F; Berman DM; Kassouf W Eur Urol Open Sci; 2023 Nov; 57():22-29. PubMed ID: 38020525 [TBL] [Abstract][Full Text] [Related]
33. Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. Hodges KB; Lopez-Beltran A; Emerson RE; Montironi R; Cheng L Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):401-10. PubMed ID: 20505509 [TBL] [Abstract][Full Text] [Related]
34. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator. Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106 [TBL] [Abstract][Full Text] [Related]
35. A molecular taxonomy for urothelial carcinoma. Sjödahl G; Lauss M; Lövgren K; Chebil G; Gudjonsson S; Veerla S; Patschan O; Aine M; Fernö M; Ringnér M; Månsson W; Liedberg F; Lindgren D; Höglund M Clin Cancer Res; 2012 Jun; 18(12):3377-86. PubMed ID: 22553347 [TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: diagnostic implications and pitfalls. Paner GP; McKenney JK; Barkan GA; Yao JL; Frankel WL; Sebo TJ; Shen SS; Jimenez RE Am J Surg Pathol; 2011 Jun; 35(6):787-98. PubMed ID: 21572312 [TBL] [Abstract][Full Text] [Related]
37. The current status of molecular biomarkers in patients with metastatic urothelial carcinoma of the bladder. Kerr PS; Freedland SJ; Williams SB Expert Rev Mol Diagn; 2020 Feb; 20(2):127-129. PubMed ID: 31495246 [No Abstract] [Full Text] [Related]
38. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906 [TBL] [Abstract][Full Text] [Related]
40. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder. Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]